sotigalimab

BIOLOGICAL2 trials

Sponsors

M.D. Anderson Cancer Center, Apexigen America, Inc.

Conditions

CancerCancer of SkinMelanomaMelanoma (Skin)Metastatic Colorectal AdenocarcinomaMetastatic MelanomaMetastatic Pancreatic Ductal AdenocarcinomaStage IV Colorectal Cancer AJCC v7

Phase 1

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Enrolling by invitationNCT02600949

M.D. Anderson Cancer CenterMetastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IVA Colorectal Cancer AJCC v7 +3

Start: 2016-05-11End: 2027-05-31Target: 300Updated: 2026-06-17

Phase 2

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

TerminatedNCT04337931

Apexigen America, Inc.Cancer, Cancer of Skin, Melanoma +3

Start: 2019-06-12End: 2022-08-02Updated: 2024-02-13

Related Papers

Abstract CT091: Trial in progress: A phase I study of personalized neoantigen vaccination combined with PD-1 blockade and CD40 agonism in resected pancreatic ductal adenocarcinoma

Cancer Research2026-04-17